At the time of writing, Aldeyra Therapeutics Inc [ALDX] stock is trading at $4.72, up 0.75%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ALDX shares have gain 44.34% over the last week, with a monthly amount glided 20.10%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, March 2024, Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease. In a post published today on Yahoo Finance, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable resubmission of a New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease to the U.S. Food and Drug Administration (FDA). Following discussions with the FDA, Aldeyra intends to initiate a dry eye chamber clinical trial in the first half of 2024. Contingent on positive results from the planned clinical trial, NDA resubmission is expected in the second half of 2024. Based on FDA guidance, the planned review period for the potential NDA resubmission is expected to be six months.
From an analyst’s perspective:
Aldeyra Therapeutics Inc [NASDAQ: ALDX] stock has seen the most recent analyst activity on April 03, 2024, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $10 for it. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $26 on February 08, 2021. Berenberg initiated its recommendation with a Buy and recommended $32 as its price target on December 16, 2020. Jefferies started tracking with a Buy rating for this stock on October 30, 2020, and assigned it a price target of $24. In a note dated October 16, 2020, BTIG Research initiated an Buy rating and provided a target price of $29 on this stock.
For the past year, the stock price of Aldeyra Therapeutics Inc fluctuated between $1.42 and $11.97. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Aldeyra Therapeutics Inc [NASDAQ: ALDX] shares were valued at $4.72 at the most recent close of the market. An investor can expect a potential return of 111.86% based on the average ALDX price forecast.
Analyzing the ALDX fundamentals
Gross Profit Margin for this corporation currently stands at 0.33% with Operating Profit Margin at -109.0%, Pretax Profit Margin comes in at -95.62%, and Net Profit Margin reading is -93.85%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.29 and Total Capital is -0.34. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.54 points at the first support level, and at 4.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.93, and for the 2nd resistance point, it is at 5.15.
Aldeyra Therapeutics Inc [ALDX] reported earnings per share of -$0.08 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.14/share, meaning a difference of $0.06 and a surprise factor of 42.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.14 per share as compared to estimates of -$0.24 per share, a difference of $0.1 representing a surprise of 41.70%.
Ratios To Look Out For
It is important to note that Aldeyra Therapeutics Inc [NASDAQ:ALDX] has a current ratio of 6.44. Further, the Quick Ratio stands at 6.44, while the Cash Ratio is 6.42.
Transactions by insiders
Recent insider trading involved PERCEPTIVE ADVISORS LLC, 10% Owner, that happened on Apr 03 ’24 when 0.31 million shares were purchased. 10% Owner, PERCEPTIVE ADVISORS LLC completed a deal on Apr 02 ’24 to buy 0.19 million shares. Meanwhile, 10% Owner PERCEPTIVE ADVISORS LLC bought 8374.0 shares on Apr 01 ’24.
